A Top 25 global Japan headquartered pharmaceutical company selected PV Reports and PV Central after an extensive 14-month evaluation of products in the marketplace. This included a POC with hands on session for global users which was positive around user friendliness, compliance, and system maturity. The company is replacing the current Deloitte converge health reporting solution.
Scope includes:
The project is being implemented and expected to go-live in 2023.